Announcements Trials
Browse Landscape

Phase

Phase 1/2 2Phase 2 1

Status

Completed 2

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Thoracic 2

Conditions

Advanced Solid Tumor 12Solid Tumor 5Nasopharyngeal Carcinoma 5Uterine Cervical Neoplasms 4Triple Negative Breast Neoplasms 3Melanoma 3Colorectal Neoplasms 3Carcinoma, Non-Small-Cell Lung 3Carcinoma, Hepatocellular 3Sarcoma 2Recurrence 2Neoplasms 2Locally Advanced or Metastatic Solid Tumors 2Liposarcoma 2Advanced Solid Tumors 2Advanced Lung Cancer 2Stomach Neoplasms 1Squamous Cell Carcinoma of Head and Neck 1Solid Tumor, Adult 1Solid Cancer 1Small Cell Lung Carcinoma 1Pyloric Stenosis, Hypertrophic 1Pancreatic Neoplasms 1Pancreatic Cancer Metastatic 1PD-1 1Ovarian Neoplasms 1Meningeal Carcinomatosis 1Lymphoma, Large B-Cell, Diffuse 1Liver Neoplasms 1Leiomyosarcoma 1

Interventions

Injections 3toripalimab 2Carboplatin 2aflutinib 1Pemetrexed 1Paclitaxel 1Etoposide 1Docetaxel 1Cisplatin 1Chlorogenic Acid 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 1/2 × Advanced Lung Cancer × toripalimab × Clear all
NCT05664971 2025-12-02

JS004 Combined With Toripalimab and With Standard Chemotherapy Treat Patients With Advanced Lung Cancer

Shanghai Junshi Bioscience Co., Ltd.

Phase 1/2 Completed
119 enrolled
Thoracic

Advanced Lung Cancer

NCT05000684 2025-02-20

Study of JS004 Combined With Toripalimab for Advanced Lung Cancer

Shanghai Junshi Bioscience Co., Ltd.

Phase 1/2 Completed
67 enrolled
Thoracic

Advanced Lung Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡